Showing results (61-70 of 83) with videos related to
Sort By:
Pageof 9
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 18, 2018
Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing miceAli Fan, Jiali Wei, Mengru Yang, et al.European Journal of Medicinal Chemistry|January 9, 2020
Discovery of 6'-chloro-N-methyl-5'-(phenylsulfonamido)-[3,3'-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of PlasmodiumXiaofei Liang, Zongru Jiang, Zhenghui Huang, et al.Acta Pharmaceutica Sinica. B|March 7, 2020
Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agentZongru Jiang, Li Wang, Xuesong Liu, et al.European Journal of Pharmacology|May 10, 2023
Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatmentAoli Wang, Juan Liu, Xixiang Li, et al.Signal Transduction and Targeted Therapy|April 4, 2023
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitusJunjie Wang, Ziping Qi, Yun Wu, et al.Journal of Medicinal Chemistry|August 29, 2022
Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 DiabetesYun Wu, Ziping Qi, Beilei Wang, et al.Journal of Medicinal Chemistry|November 12, 2020
Discovery of (<i>S</i>)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3<i>H</i>)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary DiseaseFeng Li, Xiaofei Liang, Zongru Jiang, et al.European Journal of Medicinal Chemistry|May 20, 2023
Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitorQianmao Liang, Beilei Wang, Fengming Zou, et al.European Journal of Medicinal Chemistry|September 19, 2020
Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutantsBeilei Wang, Wentao Zhang, Xuesong Liu, et al.Journal of Medicinal Chemistry|October 19, 2021
Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell LymphomasBin Zhou, Xiaofei Liang, Husheng Mei, et al.Pageof 9